ArticleEuropean radiology2026
Low-dose vs standard-dose photon-counting CT for myopathy-associated interstitial lung disease: a prospective feasibility study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectivesTo evaluate the clinical utility of photon counting computed tomography (PCCT)-derived quantitative parameters for assessing interstitial lung disease (ILD) burden in patients with inflammatory idiopathic myopathy (IIM), comparing standard-dose (SD) and tin-filtered low-dose (LD) protocols, and to assess the added value of ultrathin reconstructions. MATERIALS AND
methodsIn this single-centre prospective study (September 2023-November 2024), outpatients with IIM-ILD underwent two consecutive PCCT scans. Quantitative ILD features were extracted using a commercial deep-learning software (ContextFlow ADVANCE Chest CT). Primary analyses compared LD 1.0 mm with SD 1.0 mm reconstructions using Bland-Altman analysis, with exploratory analyses of ultrathin (0.4 mm) reconstructions. Correlation analyses between deep learning-derived quantitative parameters, visual assessment, and pulmonary function tests were performed.
resultsForty-eight adults with IIM-ILD (40 females; mean age, 53.88 ± 11.13 years) were included. The LD protocol achieved a substantial dose reduction (CTDIvol: 0.77 vs 5.40 mGy) while maintaining good agreement with SD (mean net differences [MNDs] < 1% for all patterns). LD-1.0 mm protocol yielded higher volume of ground-glass opacity (MND, 0.98%) and lower volume of fibrosis extent (MND, -0.64%). Reticular pattern showed strong association with FVC% (rho
conclusionLD PCCT serves as a radiation-sparing alternative for quantitative disease assessment. Ultrathin reconstructions provide limited additional value. Future longitudinal studies are warranted to validate the performance of LD PCCT for disease monitoring. KEY POINTS: Question Can LD photon-counting CT provide robust quantitative assessment of ILD burden in patients with inflammatory myopathy compared with SD imaging? Findings Deep learning segmentation yielded LD ILD patterns that closely matched SD results, with all MNDs below 1%. Clinical relevance LD PCCT maintains quantitative robustness and physiological validity for IIM-ILD assessment, with total disease burden showing good agreement with the SD protocol, offering a radiation-sparing alternative without compromising CT-physiology correlation.
Indexed as
Identifiers
42878810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.